While setmelanotide, a melanocortin-4 receptor agonist, may be an effective therapy for obesity in these conditions (especially BBS), its cost limits accessibility for many patients. The gene discussed is MC4R; the disease is obesity due to melanocortin 4 receptor deficiency.